

AD\_\_\_\_\_

AWARD NUMBER: DAMD17-03-1-0417

TITLE: Prognostic Value of the K303R Estrogen Receptor  $\alpha$  Mutation in Breast Cancer

PRINCIPAL INVESTIGATOR: Matthew H. Herynk, Ph.D.  
Suzanne A.W. Fuqua, Ph.D.

CONTRACTING ORGANIZATION: Baylor College of Medicine  
Houston, Texas 77030

REPORT DATE: June 2004

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b>					
1. REPORT DATE (DD-MM-YYYY) 01-06-2004		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 1 Jun 2003 – 31 May 2004	
4. TITLE AND SUBTITLE  Prognostic Value of the K303R Estrogen Receptor $\alpha$ Mutation in Breast Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER DAMD17-03-1-0417	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S)  Matthew H. Herynk, Ph.D. and Suzanne A.W. Fuqua, Ph.D.  E-Mail: <a href="mailto:mherynk@breastcenter.tmc.edu">mherynk@breastcenter.tmc.edu</a>				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  Baylor College of Medicine Houston, Texas 77030				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT  The estrogen receptor (ER) $\alpha$ plays a major role in breast tumor progression, we have recently discovered a somatic mutation (A908G) that leads to a lysine to arginine (K303R) amino acid change. Here we proposed to study if the K303R ER $\alpha$ mutation is prognostic clinical factor for invasive breast cancer. Our initial studies have indicated that the mutation is present in approximately 53% of invasive breast cancers. Additionally, the mutation was more prevalent in node-positive breast cancer versus node-negative breast cancer (85% vs. 38%, respectively). Specific Aim 1 has been completed and we are proceeding with specific Aim 2. Analyzing a larger patient population with long-term clinical follow-up. In the near future we will begin creating the expression vectors and cell lines required to complete specific Aim 3. While our initial data suggest that the K303R ER $\alpha$ mutation may be involved in tumor progression and metastasis, completion of specific Aims 2 and 3 will confirm these results.					
15. SUBJECT TERMS estrogen receptor, mutation, prognostic factor, breast cancer					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	7	19b. TELEPHONE NUMBER (include area code)

## Table of Contents

Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	5
Reportable Outcomes.....	5
Conclusions.....	5
Bibliography.....	5
References.....	5
Appendices.....	6

## *Annual Report*

### **INTRODUCTION**

The estrogen receptor (ER)  $\alpha$  plays a major role in breast tumor progression and is an important target for hormonal therapy. We have recently discovered a somatic mutation (A908G) in the hinge domain of ER $\alpha$  that leads to a lysine to arginine (K303R) amino acid change (1). Initially we have identified this mutation in 30% of breast hyperplasias and 60% of invasive breast cancers. The presence of the K303R ER $\alpha$  mutation confers hypersensitivity to estrogen thereby increasing transcriptional activity at very low concentrations of estrogen in *in vitro* assays. Additionally, we have recently shown that the presence of the K303R mutation creates a new PKA and PAK1 phosphorylation site (2). While this data would suggest that the K303R ER $\alpha$  expression would confer more aggressive phenotype for breast cancers, the prognostic value of this mutation remains to be determined. Additionally, the role, if any, of the K303R ER $\alpha$  mutation in breast tumor metastasis has not been defined. This proposal seeks to determine the clinical impact of the K303R ER $\alpha$  mutation on breast cancer prognosis through the following specific aims:

1. To determine the precise frequency of the mutation in breast cancer, and its association with node-positive cancers.
2. To ask how the mutation is correlated with proliferative potential and poorer prognosis of clinical breast cancer.
3. To study metastatic behavior of K303R-expressing breast cancer cell lines in *in vivo* models.

### **BODY**

#### **Specific Aim 1**

To determine the precise frequency of the mutation in breast cancer, and its association with node-positive cancers, we have refined our microdissection and *SNaPshot* primer extension sequencing techniques. While 38% (10/26) of the node-negative breast cancers demonstrated the K303R ER $\alpha$  mutation, 85% of the node-positive breast cancers from node-positive breast cancers contained the mutation ( $p < 0.001$ ). While this mutation was present in 18 samples; ligand binding assays showed that only 16 of these samples were positive for ER expression. This result demonstrates that the mutation is present even in ER $\alpha$  negative tumors, and this may suggest that ER $\alpha$  expression may have been lost in some tumors during progression. Robertson (3) has estimated that about 20% of metastatic tumors from an ER-positive primary cancer can lose ER during metastatic progression.

#### **Specific Aim 2**

Determining if this mutation is correlated with poorer prognosis requires analysis of tumor samples with long-term clinical follow-up. As we have not begun to analyze these samples, we have not started work on this aim. We anticipate that completion of this Aim will confirm our initial studies.

#### **Specific Aim 3**

We have not started work on specific Aim 3.

## KEY RESEARCH ACCOMPLISHMENTS

1. We have developed a highly sensitive and accurate method to detect the presence of the A908G mutation in ER $\alpha$ .
2. In our initial study, the presence of the mutation correlates with lymph node-positive breast cancer.

## REPORTABLE OUTCOMES

1 meeting abstract (see bibliography)  
1 review article (see bibliography)  
Continued training of post doc

## CONCLUSIONS

We have successfully completed Specific Aim 1 and are beginning to work on specific Aims 2 and 3. We have developed and refined our sequencing techniques and found preliminary results demonstrating a mutation frequency of approximately 53%. Additionally, this mutation is more prevalent in node-positive invasive breast cancers. We will now proceed with specific Aim 2, analyzing a larger patient population, with long-term clinical follow-up. As our early data indicates that the mutation is present in more advanced lymph node-positive breast cancers, it will be exciting to analyze this mutation with known clinical parameters such as tumor size, and proliferation (Ki67 or S phase fraction), as well as recurrence free survival and overall survival as outlined in specific Aim 2. This data suggests that this mutation may play an important role in breast cancer progression and metastasis. The funds for this fellowship have been well spent in determining the important clinical role of this common ER $\alpha$  mutation.

## BIBLIOGRAPHY

1. **Herynk MH**, Fuqua, SAW (Invited review) Estrogen Receptor Mutations in Human Disease. *Endocrine Reviews* 25:(6)869-898, December 2004
2. **Herynk MH**, Hopp TH, Zhang M, Cui Y, Fuqua SAW, (2004) Increased Steady State Levels of the K303R Estrogen Receptor  $\alpha$  Mutant. Proc. American Association for Cancer Research. Abs# 2862

## REFERENCES

1. Fuqua, S. A., Wiltchke, C., Zhang, Q. X., Borg, A., Castles, C. G., Friedrichs, W. E., Hopp, T., Hilsenbeck, S., Mohsin, S., O'Connell, P., and Allred, D. C. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. *Cancer Res*, 60: 4026-4029, 2000.
2. Cui, Y., Zhang, M., Pestell, R., Curran, E. M., Welshons, W. V., and Fuqua, S. A. Phosphorylation of estrogen receptor alpha blocks its acetylation and regulates estrogen sensitivity. *Cancer Res*, 64: 9199-9208, 2004.
3. Robertson, J. F. Oestrogen receptor: a stable phenotype in breast cancer. *Br J Cancer*, 73: 5-12, 1996.

## APPENDICES

### Figure Legends

Figure 1. Representative sequencing chromatograms from three invasive ductal breast tumors. Tumor 1 wild-type homozygote (panels A-C), tumor 2 heterozygote (panels D-F, and tumor 3 mutant homozygote (panels G-I) were sequenced using manual radioactive (panels A, D, G), *SNaPshot* (panel B, E, H), and dye terminator (panel C, F, I) using forward sequencing primers. Arrows indicate the WT or mutant peaks. The three-base pair combination GAA is overlined, and the 908 base position is underlined.




Fig. 1